Bronze
GenScript Biotech Corp. is a world leader in the biological reagent service industry. Headquartered in New Jersey, USA, the Group currently has a couple of R&D, production and operation centers in Nanjing and New Jersey, two production bases in Zhenjiang and Jinan. With the fast growth in developing biological reagents, the Company now expands its business into immunotherapy, contract development and manufacturing organization (CDMO), lab equipment and industrial microbiology applications. To support these businesses, it has established open and innovation-driven technological platforms, GMP facilities for pre-clinical drug discovery and pharmaceutical product development and a full-range industrial microbial R&D and industrialization platform for enzyme screening, GMP plasmid and virus production, antibody drug discovery (Bispecific antibodies technology; Hybridoma technology; Humanized Antibody technology; Phage display technology), genetic engineering, protein engineering and fermentation process optimization. The Company is uniquely positioned and well equipped to further fulfill its mission in making people and nature healthier through biotechnology.
The GenScript cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit, also known as SARS-CoV-2 Surrogate Virus Neutralization Test (sVNT) Kit, is the first-in-the-world "rapid smart test kit", with the capability of measuring functional neutralizing antibodies (NAbs) within an hour in most research or clinical labs. The cPass™ technology allows for the rapid detection of total neutralizing antibodies (NAbs) in a sample by mimicking the interaction between the virus and the host cell. In order for a virus to infect a host cell, a viral receptor binding protein (RBD) first needs to interact with the host cell's membrane receptor protein (ACE2). The virus-host interaction and subsequent viral infection of the host cell leads to the activation of an individual's immune response which generates a population of antibodies against the virus. Some of these antibodies can bind to the virus, but not necessarily block viral infection. Other antibodies can bind to the RBD in a way that blocks the interaction with the ACE2 receptor. The cPass™ technology helps to distinguish whether a sample contains NAbs that may specifically block the interaction and therefore the viral entry into the host cell.